Braeburn develops next generation therapies for opioid use disorder and for chronic pain with individualized dosing regimens and delivery options.


Our Programs

Opioid Use Disorder: Braeburn’s New Drug Application (NDA) for BRIXADI™ (CAM2038), our extended-release buprenorphine medication developed for subcutaneous weekly and monthly dosing, has received Tentative Approval from FDA. Learn more about BRIXADI’s clinical trial results and Tentative Approval here.

Chronic Pain: Braeburn is also investigating CAM2038 in opioid tolerant patients with chronic pain as part of its ongoing pivotal Phase III program. Learn more about CAM2038’s clinical trial results here.

Have a product related medical question?


Watch the video above for a description of FluidCrystal® Injection Depot Technology. FluidCrystal® Injection Depot Technology is developed by Camurus.

Define the future at Braeburn...together.

Join Our Team